Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.59 |
| ▸ | FPR2 | P25090 | 2/20 | 0.49 |
| ▸ | FPR1 | P21462 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4721528 | 0.89 | ROCK2 (0.62) | ROCK2FPR2FPR1CHRM2CHRM4 | |
| SCHEMBL18083927 | 0.83 | ROCK2 (0.64) | ROCK2FPR2FPR1MEN1KMT2A | |
| SCHEMBL17080069 | 0.81 | ROCK2 (0.46) | ROCK2FPR2FPR1CYP2C9CYP2C19 | |
| SCHEMBL17080107 | 0.81 | FPR2 (0.46) | ROCK2FPR2FPR1MEN1KMT2A | |
| SCHEMBL17080007 | 0.81 | ROCK2 (0.49) | ROCK2FPR2FPR1MEN1KMT2A | |
| SCHEMBL17080096 | 0.80 | ROCK2 (0.49) | ROCK2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL17080024 | 0.80 | ROCK2 (0.47) | ROCK2HDAC8HDAC6HDAC1 | |
| SCHEMBL9309143 | 0.79 | ROCK2 (0.52) | ROCK2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL17079976 | 0.79 | ROCK2 (0.45) | ROCK2FPR2HDAC6 | |
| SCHEMBL16914928 | 0.78 | ROCK2 (0.50) | ROCK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110049977-B | Lactam, cyclic urea and carbamate and triazolone derivatives as potent and selective ROCK inhibitors | 百时美施贵宝公司 | 2022-01-18 | — | — | CN | disclosed |
| US-10730858-B2 | Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730858-B2 | Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3481816-B1 | LACTAM, CYCLIC UREA AND CARBAMATE, AND TRIAZOLONE DERIVATIVES AS POTENT AND SELECTIVE ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3481816-B1 | LACTAM, CYCLIC UREA AND CARBAMATE, AND TRIAZOLONE DERIVATIVES AS POTENT AND SELECTIVE ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20190300510-A1 | LACTAM, CYCLIC UREA AND CARBAMATE, AND TRIAZOLONE DERIVATIVES AS POTENT AND SELECTIVE ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190300510-A1 | LACTAM, CYCLIC UREA AND CARBAMATE, AND TRIAZOLONE DERIVATIVES AS POTENT AND SELECTIVE ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-03 | — | — | US | disclosed |
| EP-3116877-A1 | CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015136463-A1 | CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015136463-A1 | CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300510-A1 | LACTAM, CYCLIC UREA AND CARBAMATE, AND TRIAZOLONE DERIVATIVES AS POTENT AND SELECTIVE ROCK INHIBITORS | MYLK, ROCK1, ROCK2 | ROCK2 3/4885FPR2 4495/4885FPR1 3806/4885 |
| US-10730858-B2 | Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors | MYLK, ROCK1, MYLK2 | ROCK2 7/4885FPR2 4416/4885FPR1 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.